Previous research has shown that HIV-specific CD8 T-cell responses directed against five genetically conserved HIV-1 protein ...

HIV antivirals may be the key to stopping HTLV-1, a deadly virus with no cure. In a decade-long study, researchers ...

Results from early-stage trial show that 80% of participants who received one of two HIV vaccine candidates produced antibodies against viral proteins.

We may be a step closer to a highly effective mRNA vaccine against HIV, but tests so far reveal that the approach can cause ...

Receiving treatment within the first month of life could protect children for at least three years, a study suggests.

In 2024, studies suggested that lenacapavir, already used to treat people with HIV, was nearly 100% effective in stopping ...

In a recent landmark study, scientists have unveiled how HIV-1 penetrates the cell's nuclear barrier—a discovery that could reshape antiviral strategies. The research, led by Professor Peijun Zhang, ...

To find out what may be behind these numbers, Dr. Ann Khalsa, a clinician at the Valleywise Health McDowell Clinic spoke with ...

Scientists used a mRNA-based vaccine to reliably trigger antibodies that block HIV infection in people and monkeys ...

Declining investment in global health surveillance, research, and scientific innovation are happening as the need for vigilance has never been greater, writes Robert C. Gallo.

Explore the HIV market with our comprehensive report, analyzing disease overview, epidemiology, and current treatments. Discover unmet needs, R&D strategies, and market trends from 2023-2033 in ...

The Midwest AIDS Training and Education Center’s funding will be cut completely in the current budget proposal for fiscal ...